Ad is loading...
GMED
Price
$84.91
Change
+$1.32 (+1.58%)
Updated
Nov 21 closing price
90 days until earnings call
PAVM
Price
$1.01
Change
-$0.02 (-1.94%)
Updated
Nov 21 closing price
Ad is loading...

GMED vs PAVM

Header iconGMED vs PAVM Comparison
Open Charts GMED vs PAVMBanner chart's image
Globus Medical
Price$84.91
Change+$1.32 (+1.58%)
Volume$1.75M
CapitalizationN/A
PAVmed
Price$1.01
Change-$0.02 (-1.94%)
Volume$42.92K
CapitalizationN/A
GMED vs PAVM Comparison Chart
Loading...
GMED
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PAVM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
GMED vs. PAVM commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMED is a Buy and PAVM is a StrongSell.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (GMED: $84.91 vs. PAVM: $1.01)
Brand notoriety: GMED and PAVM are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: GMED: 199% vs. PAVM: 97%
Market capitalization -- GMED: $7.19B vs. PAVM: $17.23M
GMED [@Medical Specialties] is valued at $7.19B. PAVM’s [@Medical Specialties] market capitalization is $17.23M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMED’s FA Score shows that 1 FA rating(s) are green whilePAVM’s FA Score has 0 green FA rating(s).

  • GMED’s FA Score: 1 green, 4 red.
  • PAVM’s FA Score: 0 green, 5 red.
According to our system of comparison, GMED is a better buy in the long-term than PAVM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMED’s TA Score shows that 3 TA indicator(s) are bullish while PAVM’s TA Score has 2 bullish TA indicator(s).

  • GMED’s TA Score: 3 bullish, 4 bearish.
  • PAVM’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, GMED is a better buy in the short-term than PAVM.

Price Growth

GMED (@Medical Specialties) experienced а +4.70% price change this week, while PAVM (@Medical Specialties) price change was -7.34% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.47%. For the same industry, the average monthly price growth was -1.10%, and the average quarterly price growth was -2.69%.

Reported Earning Dates

GMED is expected to report earnings on Feb 20, 2025.

PAVM is expected to report earnings on May 14, 2024.

Industries' Descriptions

@Medical Specialties (+0.47% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMED($7.19B) has a higher market cap than PAVM($17.2M). GMED YTD gains are higher at: 59.336 vs. PAVM (-71.190). GMED has higher annual earnings (EBITDA): 347M vs. PAVM (-75.74M). GMED has more cash in the bank: 518M vs. PAVM (19.6M). PAVM has less debt than GMED: PAVM (48.7M) vs GMED (520M). GMED has higher revenues than PAVM: GMED (1.57B) vs PAVM (2.45M).
GMEDPAVMGMED / PAVM
Capitalization7.19B17.2M41,814%
EBITDA347M-75.74M-458%
Gain YTD59.336-71.190-83%
P/E Ratio49.65N/A-
Revenue1.57B2.45M63,948%
Total Cash518M19.6M2,643%
Total Debt520M48.7M1,068%
FUNDAMENTALS RATINGS
GMED vs PAVM: Fundamental Ratings
GMED
PAVM
OUTLOOK RATING
1..100
2322
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
52
Fair valued
PROFIT vs RISK RATING
1..100
40100
SMR RATING
1..100
87100
PRICE GROWTH RATING
1..100
3959
P/E GROWTH RATING
1..100
4100
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAVM's Valuation (52) in the Medical Specialties industry is somewhat better than the same rating for GMED (87). This means that PAVM’s stock grew somewhat faster than GMED’s over the last 12 months.

GMED's Profit vs Risk Rating (40) in the Medical Specialties industry is somewhat better than the same rating for PAVM (100). This means that GMED’s stock grew somewhat faster than PAVM’s over the last 12 months.

GMED's SMR Rating (87) in the Medical Specialties industry is in the same range as PAVM (100). This means that GMED’s stock grew similarly to PAVM’s over the last 12 months.

GMED's Price Growth Rating (39) in the Medical Specialties industry is in the same range as PAVM (59). This means that GMED’s stock grew similarly to PAVM’s over the last 12 months.

GMED's P/E Growth Rating (4) in the Medical Specialties industry is significantly better than the same rating for PAVM (100). This means that GMED’s stock grew significantly faster than PAVM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMEDPAVM
RSI
ODDS (%)
Bearish Trend 1 day ago
70%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
66%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
64%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 8 days ago
86%
Declines
ODDS (%)
Bearish Trend 9 days ago
58%
Bearish Trend 30 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
73%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
59%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
GMED
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PAVM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FCPI45.800.54
+1.19%
Fidelity Stocks for Inflation ETF
PFM47.290.46
+0.98%
Invesco Dividend Achievers™ ETF
PEX28.250.15
+0.53%
ProShares Global Listed Private Equity
DBEF41.440.09
+0.22%
Xtrackers MSCI EAFE Hedged Equity ETF
ECNS25.83-0.29
-1.11%
iShares MSCI China Small-Cap ETF

GMED and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMED has been loosely correlated with ATEC. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if GMED jumps, then ATEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMED
1D Price
Change %
GMED100%
+1.58%
ATEC - GMED
45%
Loosely correlated
+2.82%
MYGN - GMED
39%
Loosely correlated
-1.18%
OFIX - GMED
37%
Loosely correlated
-1.01%
INGN - GMED
34%
Loosely correlated
-2.64%
FNA - GMED
34%
Loosely correlated
+0.77%
More

PAVM and

Correlation & Price change

A.I.dvisor tells us that PAVM and NNOX have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PAVM and NNOX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAVM
1D Price
Change %
PAVM100%
-1.94%
NNOX - PAVM
26%
Poorly correlated
+4.58%
GMED - PAVM
26%
Poorly correlated
+1.58%
CVRX - PAVM
25%
Poorly correlated
+9.25%
LUCD - PAVM
25%
Poorly correlated
-0.10%
RVTY - PAVM
25%
Poorly correlated
-0.21%
More